Of the four receptors, Adora2a and Adora2b have been reported as high in PDAC and are overexpressed in the pancreas during pancreatic cancer; yet only high expression of Adora2b receptor was shown to correlate with significantly reduced survival in PDAC patients. The gene discussed is ADORA2A; the disease is pancreatic neoplasm.